Revital Nimri1, Ido Muller1, Eran Atlas1, Shahar Miller1, Aviel Fogel1, Natasa Bratina2, Olga Kordonouri3, Tadej Battelino4, Thomas Danne3, Moshe Phillip5. 1. The Jesse Z. and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petah Tikva, Israel. 2. Department of Pediatric Endocrinology, Diabetes and Metabolism, University Medical Center, University Children's Hospital, Ljubljana, Slovenia. 3. Diabetes Center for Children and Adolescents, AUF DER BULT, Kinder- und Jugendkrankenhaus, Hannover, Germany. 4. Department of Pediatric Endocrinology, Diabetes and Metabolism, University Medical Center, University Children's Hospital, Ljubljana, Slovenia Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. 5. The Jesse Z. and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petah Tikva, Israel Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel mosheph@post.tau.ac.il.
Abstract
OBJECTIVE: We evaluated the effect of the MD-Logic system on overnight glycemic control at patients' homes. RESEARCH DESIGN AND METHODS: Twenty-four patients (aged 12-43 years; average A1c 7.5 ± 0.8%, 58.1 ± 8.4 mmol/mol) were randomly assigned to participate in two overnight crossover periods, each including 6 weeks of consecutive nights: one under closed loop and the second under sensor-augmented pump (SAP) therapy at patients' homes in real-life conditions. The primary end point was time spent with sensor glucose levels below 70 mg/dL (3.9 mmol/L) overnight. RESULTS: Closed-loop nights significantly reduced time spent in hypoglycemia (P = 0.02) and increased the percentage of time spent in the target range of 70-140 mg/dL (P = 0.003) compared with nights when the SAP therapy was used. The time spent in substantial hyperglycemia above 240 mg/dL was reduced by a median of 52.2% (interquartile range [IQR] 4.8, 72.9%; P = 0.001) under closed-loop control compared with SAP therapy. Overnight total insulin doses were lower in the closed-loop nights compared with the SAP nights (P = 0.04). The average daytime glucose levels after closed-loop operation were reduced by a median of 10.0 mg/dL (IQR -2.7, 19.2; P = 0.017) while lower total insulin doses were used (P = 0.038). No severe adverse events occurred during closed-loop control; there was a single event of severe hypoglycemia during a control night. CONCLUSIONS: The long-term home use of automated overnight insulin delivery by the MD-Logic system was found to be a feasible, safe, and an effective tool to reduce nocturnal hypoglycemia and improve overnight glycemic control in subjects with type 1 diabetes.
RCT Entities:
OBJECTIVE: We evaluated the effect of the MD-Logic system on overnight glycemic control at patients' homes. RESEARCH DESIGN AND METHODS: Twenty-four patients (aged 12-43 years; average A1c 7.5 ± 0.8%, 58.1 ± 8.4 mmol/mol) were randomly assigned to participate in two overnight crossover periods, each including 6 weeks of consecutive nights: one under closed loop and the second under sensor-augmented pump (SAP) therapy at patients' homes in real-life conditions. The primary end point was time spent with sensor glucose levels below 70 mg/dL (3.9 mmol/L) overnight. RESULTS: Closed-loop nights significantly reduced time spent in hypoglycemia (P = 0.02) and increased the percentage of time spent in the target range of 70-140 mg/dL (P = 0.003) compared with nights when the SAP therapy was used. The time spent in substantial hyperglycemia above 240 mg/dL was reduced by a median of 52.2% (interquartile range [IQR] 4.8, 72.9%; P = 0.001) under closed-loop control compared with SAP therapy. Overnight total insulin doses were lower in the closed-loop nights compared with the SAP nights (P = 0.04). The average daytime glucose levels after closed-loop operation were reduced by a median of 10.0 mg/dL (IQR -2.7, 19.2; P = 0.017) while lower total insulin doses were used (P = 0.038). No severe adverse events occurred during closed-loop control; there was a single event of severe hypoglycemia during a control night. CONCLUSIONS: The long-term home use of automated overnight insulin delivery by the MD-Logic system was found to be a feasible, safe, and an effective tool to reduce nocturnal hypoglycemia and improve overnight glycemic control in subjects with type 1 diabetes.
Authors: Sue A Brown; Marc D Breton; Stacey M Anderson; Laura Kollar; Patrick Keith-Hynes; Carol J Levy; David W Lam; Camilla Levister; Nihat Baysal; Yogish C Kudva; Ananda Basu; Vikash Dadlani; Ling Hinshaw; Shelly McCrady-Spitzer; Daniela Bruttomesso; Roberto Visentin; Silvia Galasso; Simone Del Favero; Yenny Leal; Federico Boscari; Angelo Avogaro; Claudio Cobelli; Boris P Kovatchev Journal: J Clin Endocrinol Metab Date: 2017-10-01 Impact factor: 5.958
Authors: Jordan E Pinsker; Joon Bok Lee; Eyal Dassau; Dale E Seborg; Paige K Bradley; Ravi Gondhalekar; Wendy C Bevier; Lauren Huyett; Howard C Zisser; Francis J Doyle Journal: Diabetes Care Date: 2016-06-11 Impact factor: 19.112
Authors: Darrell M Wilson; Peter M Calhoun; David M Maahs; H Peter Chase; Laurel Messer; Bruce A Buckingham; Tandy Aye; Paula K Clinton; Irene Hramiak; Craig Kollman; Roy W Beck Journal: Diabetes Technol Ther Date: 2015-03-11 Impact factor: 6.118
Authors: Joon Bok Lee; Eyal Dassau; Ravi Gondhalekar; Dale E Seborg; Jordan E Pinsker; Francis J Doyle Journal: Ind Eng Chem Res Date: 2016-10-27 Impact factor: 3.720